Erin Dalzell

Erin Meister Dalzell is an experienced professional in the field of cell and gene therapy, currently serving as Associate Director and CMC Lead at BlueRock Therapeutics since January 2023. Previously, Erin held various roles at bluebird bio from February 2016 to January 2023, culminating as Senior Process Engineer II in MSAT, with a focus on technology transfer and process development for autologous gene therapy targeting Sickle Cell Disease. Prior experience includes positions as Senior Medical Technologist at Massachusetts General Hospital's Cellular Therapeutics and Transplantation Laboratory and work at Genzyme as an intern in Total Protein Research. Erin holds a Bachelor of Science degree in Clinical Laboratory Science from the University of Massachusetts Dartmouth, earned in 2009.